GlassScriptPhysician profile
Kaoutar Tlemcani
NPI 1023238862
$8,043.18
in general payments reported to CMS, 2019-2025
19 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,190 · 2020: $322 · 2021: $59.90 · 2022: $136 · 2023: $440 · 2024: $1,750 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,625 · Food and Beverage: $612 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,625.00 |
| Food and Beverage | $611.57 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,126.75 | 2019-2024 | |
| Puma Biotechnology, INC. | $1,263.54 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $265.78 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $237.92 | 2024-2025 | Reblozyl, Breyanzi |
| Janssen Pharmaceuticals, INC | $186.02 | 2019-2020 | |
| Astellas Pharma US INC | $172.45 | 2020-2023 | Padcev |
| Genentech USA, INC. | $111.93 | 2019-2020 | |
| Janssen Biotech, INC. | $108.85 | 2023 | Erleada |
| Merck Sharp & Dohme LLC | $106.04 | 2019-2023 | Lynparza, Keytruda |
| Amgen INC. | $102.07 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Seagen INC. | $61.98 | 2022-2023 | Tivdak |
| Celgene Corporation | $46.46 | 2019-2025 | Reblozyl |
| Immunogen, INC. | $44.73 | 2023 | Elahere |
| Daiichi Sankyo INC. | $37.04 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23.18 | 2020 | |
| Taiho Oncology, INC. | $21.01 | 2019 | |
| Lilly USA, LLC | $17.51 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaoutar Tlemcani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.